Research at AMILI | Pioneering Microbiome Research & Innovation

Pioneering Gut
Microbiome Research
for Healthier Futures

Collaborating with academic, healthcare, and industry leaders to advance the science of the Asian gut microbiome.

Our Microbiome Research

At AMILI, we are at the forefront of gut health and microbiome research, driving transformative breakthroughs that are paving the way for healthier futures. Our commitment to innovation and scientific excellence has made us a trusted partner for leading academic institutions, research organizations, and industry collaborators. By working closely with universities, healthcare systems, and research entities, we aim to uncover new insights into the gut microbiome and its critical role in human health.

Our Research Partners

We believe that partnerships are the key to advancing science. Through collaboration, we not only strengthen our research capabilities but also contribute to the collective understanding of how our gut microbiome impacts various aspects of health, including digestion, immunity, and disease prevention. Our ongoing research programs focus on various cutting-edge areas, such as gut health testing, probiotics, and faecal microbiota transplants (FMT).
‍
We are proud to collaborate with leading universities, hospitals, and research organisations in Singapore and abroad. Some of our key partners include:

These partnerships enable AMILI to stay at the cutting edge of microbiome research and develop innovative solutions that can improve health outcomes across diverse populations.

Research Partners

AMILI is Southeast Asia’s first and only precision gut microbiome company, making us a leader in advancing microbiome research and developing innovative solutions to improve human health. Our pioneering work focuses on the Asian gut microbiome, and we are proud to have built the largest database of Asian gut microbiomes in the region. This unique position allows us to offer Asian-centric probiotics and insights, filling a significant gap in the research landscape where the majority of microbiome insights are currently based on European populations.

As a company founded by academic doctors and scientists, AMILI is committed to advancing microbiome science through collaboration with universities, healthcare organisations, and industry leaders. Our partnerships enable us to leverage cutting-edge research and clinical expertise to translate scientific discoveries into tangible products and services that improve health outcomes.

Our Research Focus Area

We are dedicated to exploring the critical role the microbiome plays in health and wellness, including its influence on metabolism, immunity, and overall well-being. Through our research, we aim to develop personalised approaches to optimise gut health and enhance quality of life.

The microbiome’s impact on cancer development and progression is an area of intense focus. We are investigating how imbalances in the microbiome may contribute to diseases like colorectal cancer and liver cancer, and have developed microbiome-based biomarkers for early detection, prognosis, and therapeutic intervention. We pioneered Faecal Microbiota Transplant in Asia, and have transplanted in cancer patients successfully, leading to remission.

Understanding how individuals respond to microbiome-based therapies is key to developing effective treatments. Our research seeks to identify microbial signatures that influence responses to such therapies, enabling more personalized and effective treatments for patients.

Key Research Projects

AMILI’s clinical research spans a variety of areas, including health, oncology, and aging, with multiple exciting partnerships underway:

One amazing research project underway is one for A*STAR, Researching Effects on Microbiome from Ethnic Diets and natural product Yields (REMEDY) as well as post antibiotic recovery. This research aims to quantify how personalised nutrition can enhance the microbiome.

With KK Women’s and Children’s Hospital (KKH) and the Lien Foundation, AMILI is exploring the role of the microbiome during preconception, pregnancy, and early childhood. This research aims to uncover the microbial factors that influence metabolic, psychological, and early childhood health outcomes.

We are collaborating with the National University Health System (NUHS) and other partners to investigate the relationship between the gut microbiome and colorectal cancer. This research focuses on identifying microbiome imbalances that may accelerate cancer development and discovering microbial signatures that can serve as biomarkers for early detection and prognosis.

The gut microbiome’s influence on liver health is another key area of our research. AMILI is partnering with the National Cancer Centre Singapore (NCCS) to study microbiome-based biomarkers for early detection of hepatocellular carcinoma (HCC), a type of liver cancer.

AMILI is working with the Yong Loo Lin School of Medicine at NUS on the SG70 cohort study, which is investigating the link between the gut microbiome and healthy aging. This longitudinal study aims to explore microbiome-related factors that contribute to elderly frailty and may help in developing interventions to slow down, halt, or even reverse the aging process.

The GMM study examines how cholecystectomy (for gallstones) and ERCP (for bile duct stone extraction) affect the gut microbiome. Given links between cholecystectomy and colorectal cancer or metabolic syndrome, the study aims to: (1) assess gut microbiome changes post-cholecystectomy and their clinical impact, (2) analyse systemic metabolome alterations, (3) explore microbiome-metabolome interactions, and (4) evaluate ERCP’s effects on the gut microbiome.

Our Unique Advantage: The Asian Gut Microbiome

AMILI is focused on advancing the science of the Asian gut microbiome, which is distinct from Western microbiomes due to genetic, dietary, and environmental factors. Our expansive database of Asian microbiomes is the biggest in Asia, allowing us to offer insights and develop probiotics that are tailored specifically to the needs of Asian populations. This is a crucial step in creating precision health solutions that can deliver more effective results for individuals in the region.

Why Partner with AMILI?

> $60M in research grants awared since inception.

> 20 research studies across multiple indications from colorectal cancer to non-alcholic fatty liver disease.

> 10 partnerships with academic and industry.

Cutting-Edge Research Infrastructure
‍We offer state-of-the-art facilities and access to cutting-edge technologies for microbiome research, including advanced sequencing methods, bioinformatics, and diagnostic tools. 

Global Collaboration Network
‍Our established network of international research partners provides access to a diverse range of expertise, from clinical research to food science, genomics, and microbiome therapeutics. 

Translational Research Focus
‍We focus on turning scientific discoveries into real-world applications. Our collaborative efforts with partners aim to deliver practical solutions for improving health, from better diagnostics to effective therapeutic interventions. 

Impact-Driven Innovation
‍Our research partnerships are driven by a shared goal: to make a tangible difference in the world by advancing knowledge, improving health outcomes, and promoting wellness on a global scale. 

Key Benefits of Our Asian-Centric Library

Precision Research
for Asian Populations

By utilising microbiome strains specific to Asian populations, we eliminate the uncertainty and bias that can arise from using non-representative data. This precision allows us to deliver more accurate and relevant research outcomes.

Development of
Asian-Specific Probiotics

Our library empowers us to identify and develop probiotics that are tailored to the needs of Asian populations. These probiotics are designed to work effectively with the unique microbiome compositions found in the region, offering enhanced benefits compared to generic formulations.

Unparalleled Insights

With the largest database of its kind, our library enables us to generate insights into the gut microbiome that are specific to multi-ethnic Asian populations. These insights are invaluable for understanding gut health, disease prevention, and the development of personalised health interventions.

Advancing Gut
Microbiome Therapeutics

By leveraging the strains in our library, we can develop and validate therapeutic interventions that address health issues unique to or prevalent in Asian populations, such as metabolic disorders, colorectal cancer, and liver diseases.

A Unique Resource for Our Research Partners

Our Asian-Centric Library is not just a cornerstone of AMILI’s research but also a valuable resource for our collaborators. Academic institutions, healthcare organisations, and industry leaders partnering with AMILI gain access to this unparalleled database for their research projects, enabling groundbreaking discoveries that prioritize Asian populations.

By focusing on the Asian gut microbiome, we are ensuring that the benefits of microbiome science are inclusive and effective for the diverse populations we serve. Whether you are developing probiotics, investigating disease mechanisms, or creating personalized nutrition plans, our library provides the foundation for impactful research and innovation.

Join Us in Advancing Gut Health Research

At AMILI, we are always seeking new research partnerships that align with our mission to improve gut health globally. Whether you are an academic institution, healthcare provider, or industry partner, we invite you to explore opportunities to collaborate with us in cutting-edge research.

If you are interested in partnering with us on research initiatives or have any questions about our ongoing projects, please reach out to us. Together, we can make significant strides in advancing the science of gut health.